Compare GC-Rise Pharmaceutical vs NitroMed
Customers evaluate the quality of GC-Rise Pharmaceutical's products using the following success metrics.
Overview
GC-Rise Pharmaceutical is based in China
GC-Rise Pharmaceutical is a pharmaceutical company that aims to bring Western natural medicine with proven clinical benefits to China. The company received approval for Remifemin for natural treatment for post-menoposal symptoms from the Chinese regulatory authorities (SFDA) after successfully conducting clinical trials in China. The company has launched other products and is currently developing additional natural derived medicine in China.
NitroMed is 37 yrs old and is based in United States.
NitroMed is a pharmaceutical company and the maker of BiDil, an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as ACE inhibitors and/or beta blockers. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial.
Demo Video
Leadership
Hailei Zhang (Chief Executive Officer, President)
Kenneth M Bate (Chief Executive Officer, President)
Investors
OrbiMed Advisors and Inventages Venture Capital
Arbor Pharmaceuticals, Omega Advisors
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because GC-Rise Pharmaceutical has not claimed their profile.
Work for GC-Rise Pharmaceutical? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for GC-Rise Pharmaceutical?
Claim your profile now.
Information not available because NitroMed has not claimed their profile.
Work for NitroMed? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for NitroMed?
Claim your profile now.